Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds
Authors
Keywords
Metronomic chemotherapy, Non-Hodgkin-lymphoma, Preclinical studies, Clinical studies, Diffuse large B-Cell, T-cell lymphoma, Elderly, Geriatric assessment
Journal
CANCER LETTERS
Volume 524, Issue -, Pages 144-150
Publisher
Elsevier BV
Online
2021-10-20
DOI
10.1016/j.canlet.2021.10.018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
- (2021) Lucie Oberic et al. JOURNAL OF CLINICAL ONCOLOGY
- Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi
- (2021) Francesco Merli et al. JOURNAL OF CLINICAL ONCOLOGY
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
- (2021) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
- (2021) Chryssoula Kordella et al. Frontiers in Oncology
- Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis
- (2020) Kelu Hou et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation
- (2020) Andrés J. M. Ferreri et al. HEMATOLOGICAL ONCOLOGY
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma
- (2020) Per-Olof Thuresson et al. ADVANCES IN THERAPY
- All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma
- (2020) Maria Christina Cox et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma
- (2020) Paola Orlandi et al. JOURNAL OF CHEMOTHERAPY
- Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches
- (2020) Pamela Allen Current Oncology Reports
- Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
- (2020) Vijay Patil et al. Lancet Global Health
- Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
- (2020) Mengyang Di et al. ONCOLOGIST
- Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
- (2020) Lorenzo Falchi et al. BLOOD
- Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
- (2019) Cem Simsek et al. Journal of Oncology
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- (2019) Andrew D. Zelenetz et al. BLOOD
- The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma
- (2019) M. Christina Cox et al. INVESTIGATIONAL NEW DRUGS
- Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma
- (2019) Ke Wu et al. Cancer Medicine
- Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis
- (2019) Suresh Agarwal et al. HEMATOLOGICAL ONCOLOGY
- Comparison of complication rates and incidences associated with different peripherally inserted central catheters (PICC) in patients with hematological malignancies: a retrospective cohort study
- (2019) Nicholas Scrivens et al. LEUKEMIA & LYMPHOMA
- Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)
- (2019) Guido Gini et al. BLOOD
- The role of metronomic chemotherapy in the era of cancer immunotherapy: an oncologist’s perspective
- (2019) S. Y. Tsao Current Oncology
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors
- (2018) Paola Orlandi et al. BIOCHEMICAL PHARMACOLOGY
- Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
- (2018) Stefania Orecchioni et al. BRITISH JOURNAL OF CANCER
- Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
- (2018) Gianfranco Natale et al. CANCER LETTERS
- Treatment of Older Patients With Newly Diagnosed AML Unfit for Traditional Therapy
- (2018) Alan K. Burnett Clinical Lymphoma Myeloma & Leukemia
- Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial
- (2018) Qiu-Dan Shen et al. Lancet Haematology
- Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
- (2018) Laurens E. Franssen et al. Oncotarget
- Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma
- (2018) François Lemonnier et al. BLOOD
- Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
- (2018) Roland Christian Schelker et al. BMC CANCER
- Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma
- (2018) Hanno M. Witte et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2017) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
- (2016) Eirini Biziota et al. ANTI-CANCER DRUGS
- Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
- (2016) I. S. Nijhof et al. BLOOD
- The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin’s lymphoma
- (2016) Jiangzheng Zeng et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma
- (2016) Zhen Jin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro
- (2016) Caixing Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
- (2016) Guido Bocci et al. Nature Reviews Clinical Oncology
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
- (2015) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition
- (2015) L. MAVROEIDIS et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
- (2015) Urban Emmenegger et al. NEOPLASIA
- Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
- (2015) Chong-Sheng Chen et al. NEOPLASIA
- Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
- (2013) A. Larocca et al. BLOOD
- Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy
- (2013) Annabelle Chow et al. INVESTIGATIONAL NEW DRUGS
- De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial
- (2013) Paul A. Fields et al. JOURNAL OF CLINICAL ONCOLOGY
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model
- (2012) Ai-Xia Dou et al. Cellular & Molecular Immunology
- Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen
- (2012) Coleman Hematology
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
- (2011) Frédéric Peyrade et al. LANCET ONCOLOGY
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
- (2010) Jia Ruan et al. CANCER
- Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
- (2009) Claire Banissi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started